Recurrent Pregnancy Loss

Table of Contents

1. Overview
2. Definition and Epidemiology
3. Genetic Causes
4. Antiphospholipid Syndrome (APS)
5. Uterine Anomalies
6. Hormonal and Metabolic Causes
7. Thrombophilia
8. Unexplained RPL and Supportive Care
9. Evaluation and Workup
10. Treatment Approaches
11. Prognosis and Emotional Impact
12. Key Research Papers
13. Connections
14. Featured Videos

Overview

Recurrent pregnancy loss (RPL) — also called recurrent miscarriage — is one of the most emotionally devastating experiences a person can go through. You lose a pregnancy not once, but again and again. Each loss brings grief, confusion, and the terrifying question: Will I ever carry a baby to term?

The good news is that RPL is not untreatable. For most couples, a cause can be identified or strongly suspected after a thorough evaluation — and even when no cause is found, the majority of women will eventually have a successful pregnancy. This article explains what RPL is, what causes it, how it is investigated, and what treatments actually help.

Understanding the evidence behind each treatment is important. Some interventions have strong clinical trial support; others are commonly prescribed despite limited proof of benefit. Knowing the difference helps you have more informed conversations with your doctor and manage expectations realistically.

↑ Back to Table of Contents

Definition and Epidemiology

RPL is defined as two or more clinically recognized pregnancy losses before 20 weeks of gestation. This definition was updated by the American Society for Reproductive Medicine (ASRM) in 2020 — previously the threshold was three losses. The change reflects growing evidence that the underlying risk factors and causes are the same after two losses as after three, and that couples deserve evaluation and support earlier rather than later.

A "clinically recognized" loss means a pregnancy that was confirmed by ultrasound or pathology — not just a late or heavy period. Biochemical pregnancies (where a blood pregnancy test turns positive but no gestational sac is ever seen on ultrasound) are a gray area; current guidelines focus on clinically confirmed losses.

How common RPL is

• About 10–15% of all clinically recognized pregnancies end in miscarriage.
• RPL (two or more losses) affects approximately 2–5% of couples trying to conceive.
• Three or more consecutive losses — the older "traditional" threshold — affects about 1% of couples.
• Maternal age is a strong independent risk factor: miscarriage risk rises sharply after age 35 and steeply after 40, largely due to the increasing rate of chromosomally abnormal embryos.

Experiencing two miscarriages does not mean the third pregnancy will fail. Most women with RPL will eventually have a successful live birth, though the road is often long and painful.

↑ Back to Table of Contents

Genetic Causes

Chromosome problems are the most common cause of any individual miscarriage, accounting for roughly 50% of all early pregnancy losses. When an embryo inherits an extra or missing chromosome — a condition called aneuploidy — the pregnancy typically fails to develop normally and miscarries, usually in the first trimester.

The critical point is that most of these chromosome errors occur by chance during egg or sperm formation and are not inherited from the parents. Having one chromosomally abnormal miscarriage does not mean every future pregnancy will be the same.

Parental Chromosome Rearrangements

In a small but important subset of RPL couples — about 2–5% — one partner carries a structural rearrangement of their chromosomes called a balanced translocation. In this situation, the parent has all the right genetic material, but pieces of chromosomes have been swapped or rearranged. The parent is healthy, but when their eggs or sperm are formed, some carry an unbalanced set of chromosomes that cannot support a viable pregnancy.

Parental balanced translocations are identified by a karyotype blood test of both partners. If one partner carries a translocation:

• Options include continuing to try naturally (many couples with translocations do eventually have healthy children).
• Preimplantation genetic testing (PGT-SR) with IVF can screen embryos for chromosomal balance before transfer, significantly improving the chance of a successful pregnancy.
• Genetic counseling is commonly offered to explain the specific risks of a particular translocation.

Embryo Chromosomal Testing After Loss

When pregnancy tissue is available after a miscarriage, genetic testing of the embryo (chorionic villus or POC — products of conception — testing) can tell you whether that specific loss was due to a chromosome error. Finding aneuploidy in a miscarried pregnancy is actually somewhat reassuring — it means the loss was likely a random event, not a sign of a persistent underlying problem.

↑ Back to Table of Contents

Antiphospholipid Syndrome (APS) — Most Important Treatable Cause

Antiphospholipid syndrome (APS) is the single most important treatable cause of RPL. It accounts for roughly 15–20% of recurrent pregnancy loss, and when treated appropriately, most women with APS go on to have successful pregnancies.

APS is an autoimmune condition in which the body produces antibodies that attack phospholipid proteins — components of cell membranes involved in blood clotting. In pregnancy, these antibodies promote clotting in the tiny blood vessels of the placenta, cutting off the oxygen and nutrients the developing baby needs.

How APS Is Diagnosed

APS requires both a clinical criterion and a laboratory criterion:

• Clinical: Three or more consecutive pregnancy losses before 10 weeks, one or more losses after 10 weeks of a morphologically normal fetus, or a premature birth before 34 weeks due to placental insufficiency.
• Laboratory: Positive test for one or more of three antiphospholipid antibodies — anticardiolipin antibody (aCL), anti-beta-2 glycoprotein I (anti-β2GP1), or lupus anticoagulant (LA) — on two separate occasions at least 12 weeks apart. A single positive test is not enough to diagnose APS, because transient positive results are common, especially after an infection.

Treatment: Heparin + Low-Dose Aspirin

The treatment that works is a combination of low molecular weight heparin (LMWH, such as enoxaparin) and low-dose aspirin (typically 81 mg daily), started as soon as pregnancy is confirmed and continued throughout pregnancy.

The landmark 1996 trial by Kutteh demonstrated that this combination produced live birth rates exceeding 75% in APS patients — compared to less than 45% in women treated with aspirin alone (20 of 25 versus 11 of 25 women; the 50 women were alternately assigned, not randomized) PubMed PMID: 9065133. A Cochrane review of the evidence confirmed the benefit of combined heparin plus aspirin over aspirin alone for preventing pregnancy loss in APS PubMed PMID: 15846641.

Heparin does not cross the placenta and is considered safe for the baby. The main maternal risk is reduced bone density with long-term use, which is why monitoring and calcium/vitamin D supplementation are typically recommended.

↑ Back to Table of Contents

Uterine Anomalies

The shape of the uterus matters for pregnancy. Structural problems with the uterine cavity can interfere with how an embryo implants and receives its blood supply.

Septate Uterus — Most Common Treatable Structural Cause

The septate uterus is the most common uterine anomaly associated with RPL. During fetal development, the two tubes that fuse to form the uterus may leave a fibrous wall — called a septum — dividing part or all of the uterine cavity. An embryo that implants on the septum may receive inadequate blood supply and miscarry.

The treatment is hysteroscopic metroplasty — a minimally invasive procedure in which a thin camera is passed through the cervix into the uterus, and the septum is cut away with surgical instruments. Recovery is generally rapid. Observational studies reported better pregnancy outcomes after the procedure, but the first randomized trial (TRUST, 2021) found no improvement in live births (see Treatment Approaches).

Asherman's Syndrome (Intrauterine Adhesions)

Scar tissue (adhesions) inside the uterine cavity — often a result of prior uterine surgery, D&C procedures, or infections — can distort the uterine cavity and prevent normal implantation. This is called Asherman's syndrome. Hysteroscopic adhesiolysis (cutting the adhesions) can restore the normal cavity, though success varies with the severity of scarring.

Submucous Fibroids and Endometrial Polyps

Fibroids that push into the uterine cavity (submucous fibroids) or polyps growing from the uterine lining can interfere with implantation and may contribute to RPL. Hysteroscopic removal of these lesions is commonly offered before further pregnancy attempts.

How the Uterus Is Evaluated

Options for evaluating the uterine cavity include:

• 3D pelvic ultrasound — non-invasive, good at detecting septa and fibroids.
• Saline infusion sonogram (SIS or sonohysterogram) — saline is instilled into the cavity to improve visualization of polyps and submucous fibroids.
• Hysteroscopy — the gold standard; directly visualizes and can simultaneously treat most cavity abnormalities.
• Magnetic resonance imaging (MRI) — useful in complex cases or when differentiating a septum from a bicornuate uterus is clinically important.

↑ Back to Table of Contents

Hormonal and Metabolic Causes

Several hormonal conditions are associated with RPL and are particularly important to identify because they are highly treatable.

Progesterone and Luteal Phase Defect

Progesterone is the hormone that prepares the uterine lining for implantation and supports the early pregnancy until the placenta takes over (around 10 weeks). If progesterone production in the second half of the cycle (the luteal phase) is insufficient, implantation and early placentation may be disrupted.

Progesterone supplementation — typically as vaginal suppositories — is widely prescribed for women with RPL, particularly those with documented luteal phase deficiency. The PROMISE trial (2015, New England Journal of Medicine) randomized 836 women with unexplained recurrent miscarriage to vaginal progesterone (400 mg twice daily) or placebo from soon after a positive pregnancy test through 12 weeks: live births were 65.8% with progesterone and 63.3% with placebo, a difference of 2.5 percentage points that was not statistically significant, and adverse events did not differ PubMed PMID: 26605928. A second large trial, PRISM (2019), tested the same treatment in 4,153 women with bleeding in early pregnancy: live births after at least 34 weeks were 75% with progesterone versus 72% with placebo, not statistically significant overall (P=0.08) PubMed PMID: 31067371. What is not known: whether any subgroup of women with recurrent loss gains a clear benefit — neither large trial showed one overall. Dydrogesterone, an oral progestogen available in some countries, has also shown benefit in several trials of threatened miscarriage PubMed PMID: 22794306.

Thyroid Disease

Both overt and subclinical hypothyroidism are associated with miscarriage. Most RPL specialists aim for a thyroid-stimulating hormone (TSH) below 2.5 mIU/L in women trying to conceive or who are pregnant. If your thyroid-stimulating hormone is above this target, levothyroxine is prescribed to bring it into range. Thyroid antibodies (anti-TPO, anti-thyroglobulin) may also be tested, as thyroid autoimmunity is associated with worse pregnancy outcomes even when thyroid-stimulating hormone is normal. In women with repeated pregnancy loss, normal thyroid levels and thyroid peroxidase antibodies, the T4LIFE trial (187 women, 2022) found that levothyroxine did not raise live births: 50% with levothyroxine versus 48% with placebo; the authors state that they do not advise routine levothyroxine for this group PubMed PMID: 35298917.

Diabetes and Insulin Resistance

Poorly controlled diabetes significantly increases miscarriage risk. The target for women with diabetes trying to conceive is a hemoglobin A1c (HbA1c) below 6.5%. Insulin resistance and polycystic ovary syndrome (PCOS) — even without frank diabetes — may also contribute to RPL through disrupted endometrial receptivity.

Hyperprolactinemia

Elevated prolactin levels can suppress ovulation and impair luteal phase function. Prolactin is checked as part of a standard RPL workup. If elevated, bromocriptine or cabergoline (dopamine agonists) typically normalize levels and improve pregnancy outcomes.

↑ Back to Table of Contents

Thrombophilia

Inherited clotting disorders (thrombophilias) can increase the risk of blood clots in placental vessels, potentially contributing to pregnancy loss. The most studied inherited thrombophilias in the context of RPL include:

• Factor V Leiden mutation — the most common inherited thrombophilia in European populations; causes resistance to activated protein C.
• Prothrombin G20210A mutation — increases circulating prothrombin levels and clotting tendency.
• Protein C, Protein S, and Antithrombin deficiencies — less common but clinically significant.

A 2003 meta-analysis found significant associations between several thrombophilias and fetal loss, particularly late fetal loss (after 10–14 weeks) — PubMed PMID: 12648968.

The Evidence Problem

Despite the plausible biological rationale, the evidence that treating inherited thrombophilia with LMWH prevents miscarriage is much weaker than for APS. Multiple randomized controlled trials have failed to show a clear benefit of LMWH in women with inherited thrombophilia and RPL who do not have APS. Current guidelines generally do not recommend routine LMWH for inherited thrombophilia in RPL unless there is also a personal or strong family history of blood clots — in which case treatment is indicated for the thrombophilia itself, regardless of RPL.

This is an area of active research, and practices vary between clinicians. When heparin is proposed for a thrombophilia, the key distinction is whether it is for a documented blood clot risk or specifically for RPL, and what evidence supports that use.

↑ Back to Table of Contents

Unexplained RPL and Supportive Care

Even after a complete evaluation, no clear cause is found in roughly 50% of RPL cases. This is called "unexplained RPL," and it can feel deeply frustrating — but there is genuinely good news embedded in this diagnosis.

A 1999 observational study by Brigham, Conlon and Farquharson at a Liverpool miscarriage clinic followed 325 women with unexplained RPL who had early pregnancy monitoring — ultrasound scans every two weeks through the first trimester under a standard clinic protocol. Of the 70% who conceived again, 75% had a successful pregnancy, even without any specific medical treatment; the study had no comparison group PubMed PMID: 10548638.

This "tender loving care" (TLC) effect is thought to work through several mechanisms:

• Anxiety reduction — stress hormones may impair early pregnancy.
• Early detection of problems that can be treated (like subchorionic hematomas).
• Reassurance that the pregnancy is progressing when it is, reducing panic over every symptom.

What "Unexplained" Actually Means

An "unexplained" result does not mean nothing is wrong or that the losses were your fault. It means our current tests cannot identify the mechanism. Research continues into emerging areas including uterine natural killer cells, endometrial receptivity testing, paternal factors, and microbiome changes — but none of these investigations are currently supported by enough evidence to be recommended as standard care outside of clinical trials.

Chromosomal abnormalities in the miscarried embryos, even without a parental translocation, are the most common "hidden" explanation — particularly in older mothers. Testing the products of conception from future losses may help clarify whether this is the case for you.

↑ Back to Table of Contents

Evaluation and Workup

A thorough evaluation is commonly offered after two clinically recognized pregnancy losses. This is not a sign that something is horribly wrong — it is a way to look for any treatable cause before another pregnancy.

Tests for Both Partners

• Karyotype (chromosome analysis) — a blood test for both partners to look for balanced translocations or other structural chromosome rearrangements. This is the only test that requires testing both partners equally.

Tests for the Pregnant Partner

• Antiphospholipid antibody panel — anticardiolipin (immunoglobulin G (IgG) and immunoglobulin M (IgM)), anti-β2 glycoprotein I (immunoglobulin G and immunoglobulin M), and lupus anticoagulant. Must be repeated at least 12 weeks later to confirm a positive result before diagnosing APS.
• thyroid-stimulating hormone (TSH) — with thyroid antibodies (anti-TPO) if thyroid-stimulating hormone is abnormal or if thyroid autoimmunity is suspected.
• Prolactin — to screen for hyperprolactinemia.
• Hemoglobin A1c or fasting glucose — to screen for diabetes, especially in women with polycystic ovary syndrome risk factors.
• Uterine cavity evaluation — 3D ultrasound, saline infusion sonogram, or hysteroscopy, depending on availability and clinical suspicion.
• Progesterone level — in the luteal phase if luteal phase deficiency is suspected.
• Inherited thrombophilia screen — Factor V Leiden, Prothrombin G20210A, Protein C/S activity, Antithrombin — considered particularly in women with late losses (after 10 weeks) or a personal/family history of blood clots.

Optional: Testing the Pregnancy Tissue

• Products of conception (POC) karyotyping — if tissue is available after a miscarriage, chromosome analysis can determine whether that specific loss was due to aneuploidy. A normal (euploid) result is more concerning for a structural cause; an aneuploid result suggests a random embryo error.

↑ Back to Table of Contents

Treatment Approaches

Treatment in RPL is highly individualized based on what the evaluation finds. The most evidence-based treatments are listed below, from strongest to weakest evidence.

1. APS: LMWH + Low-Dose Aspirin (Strong Evidence)

For women who meet full diagnostic criteria for antiphospholipid syndrome, the combination of low molecular weight heparin (enoxaparin or dalteparin) plus low-dose aspirin (81 mg) is the standard of care and dramatically improves outcomes — from under 45% to over 75% live birth rates in the 1996 Kutteh trial PubMed PMID: 9065133. Treatment starts once pregnancy is confirmed and continues through delivery and several weeks postpartum (to prevent blood clots from the pregnancy-related hypercoagulable state).

2. Septate Uterus: Hysteroscopic Metroplasty (Randomized Trial Found No Benefit)

Surgical removal of a uterine septum has long been standard practice when a septum is identified, based on observational data showing improved pregnancy outcomes after metroplasty. The procedure is minimally invasive. The first randomized trial (TRUST, 2021) assigned 80 women with a septate uterus and a history of subfertility, pregnancy loss or preterm birth, at 10 centres in the Netherlands, UK, USA and Iran, to septum removal or no surgery: within a year, live births occurred in 31% (12 of 39) after surgery and 35% (14 of 40) without surgery, a difference that was not statistically significant. One woman (2.6%) had her womb punctured (uterine perforation) during surgery. The authors concluded that hysteroscopic septum resection does not improve reproductive outcomes, while noting the trial's limited size PubMed PMID: 33793794.

3. Thyroid Optimization: Levothyroxine (For Hypothyroidism; No Benefit Shown With Normal Thyroid Levels)

Many specialists prescribe levothyroxine when thyroid-stimulating hormone is above 2.5 mIU/L. Treating hypothyroidism to normal thyroid-stimulating hormone levels reduces miscarriage risk in hypothyroid women, and levothyroxine is inexpensive. For women with normal thyroid levels who carry thyroid peroxidase antibodies, the T4LIFE trial found no increase in live births (50% versus 48% on placebo) PubMed PMID: 35298917.

4. Progesterone Supplementation (Large Trial Not Significant)

The PROMISE trial found live births of 65.8% with vaginal progesterone versus 63.3% with placebo in 836 women with unexplained RPL — not a statistically significant difference PubMed PMID: 26605928. Given the low risk and cost, many RPL specialists still prescribe it. It is started as soon as a positive pregnancy test is obtained, typically continued to 12 weeks.

5. Supportive Early Pregnancy Monitoring (Observational Evidence for Unexplained RPL)

For women with unexplained RPL, a dedicated early pregnancy clinic — in the 1999 Liverpool study, ultrasound scans every two weeks through the first trimester under a standard protocol — was followed by a 75% success rate among the women who conceived, without any additional pharmacological treatment; the study was observational, with no comparison group PubMed PMID: 10548638.

6. Preimplantation Genetic Testing (PGT) with IVF

For couples with a known parental balanced translocation, PGT-SR (preimplantation genetic testing for structural rearrangements) allows embryo chromosomes to be screened before transfer, selecting only chromosomally balanced embryos. For older women with unexplained RPL, PGT-A (aneuploidy testing) can screen for chromosomally normal embryos. PGT with IVF is invasive and expensive, but may be the most effective path for specific high-risk groups.

Treatments With Insufficient Evidence

• Intravenous immunoglobulin (IVIG) — not shown to improve outcomes in randomized trials.
• Heparin for inherited thrombophilia without APS — not supported by current randomized trial evidence for RPL specifically.
• Paternal lymphocyte immunotherapy — abandoned after trials showed no benefit and potential harm.
• Empirical corticosteroids — not supported without a specific autoimmune indication.

↑ Back to Table of Contents

Prognosis and Emotional Impact

Prognosis

The overall prognosis for RPL couples is much better than many people fear when they are in the middle of multiple losses. Large longitudinal studies suggest:

• Women with two prior losses have approximately a 70–75% chance of a live birth in the next pregnancy, even without specific treatment.
• After three losses, the overall prognosis remains around 65% for a subsequent live birth — still a strong majority.
• With a treatable cause identified (especially APS or a uterine septum), success rates approach or exceed 75–85% with appropriate treatment.
• Maternal age significantly modifies these figures: older maternal age, particularly over 40, reduces live birth rates substantially, primarily due to the higher rate of aneuploid embryos; in a study of 353 karyotyped miscarriages, maternal age was the only significant predictor of a chromosomal anomaly PubMed PMID: 22888165.

RPL prognosis is not the same as infertility prognosis. Most women with RPL can get pregnant — the challenge is sustaining a pregnancy. This distinction matters clinically and emotionally.

The Emotional Toll

Recurrent pregnancy loss causes profound psychological suffering that is frequently underestimated and undertreated. Each loss triggers acute grief. But RPL also generates a specific and particularly cruel anxiety: the fear that hope itself is dangerous — that getting excited about a new pregnancy only sets you up for more devastation. This anticipatory grief can begin the moment a positive test is seen.

Research quantifies this burden: a landmark 2021 Lancet paper documented the psychological, physical, and economic costs of early pregnancy loss, including high rates of depression, anxiety, and post-traumatic stress disorder (PTSD) in women who experience RPL Search PubMed.

Psychological support is not a luxury in RPL — it is part of the treatment. Options include:

• Dedicated RPL counselors or psychologists familiar with perinatal grief.
• Support groups for pregnancy loss (in-person or online).
• Partners are often grieving too but may be less visible in the clinical process — couples counseling can help.
• Mindfulness-based interventions have shown measurable benefits for anxiety in this population.

You are allowed to grieve. You are allowed to be angry. The losses were real, and so is the suffering. A good RPL specialist team acknowledges this explicitly rather than rushing past it to the next test order.

↑ Back to Table of Contents

Key Research Papers

1. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996;174(5):1584–9. — PubMed PMID: 9065133
2. Practice Committee of the American Society for Reproductive Medicine. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril. 2012;98(5):1103–11. — Search PubMed
3. Coomarasamy A, et al. A randomized trial of progesterone in women with recurrent miscarriages (PROMISE trial). N Engl J Med. 2015;373(22):2141–8. — PubMed PMID: 26605928
4. Coomarasamy A, Devall AJ, Cheed V, et al. A randomized trial of progesterone in women with bleeding in early pregnancy (PRISM trial). N Engl J Med. 2019;380(19):1815–24. — PubMed PMID: 31067371
5. Rikken JFW, Kowalik CR, Emanuel MH, et al. Septum resection versus expectant management in women with a septate uterus: an international multicentre open-label randomized controlled trial (TRUST). Hum Reprod. 2021;36(5):1260–7. — PubMed PMID: 33793794
6. van Dijk MM, Vissenberg R, Fliers E, et al. Levothyroxine in euthyroid thyroid peroxidase antibody positive women with recurrent pregnancy loss (T4LIFE trial): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(5):322–9. — PubMed PMID: 35298917
7. Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005;(2):CD002859. — PubMed PMID: 15846641
8. Quenby S, et al. Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss. Lancet. 2021;397(10285):1658–67. — PubMed PMID: 33915094
9. Carp H. A systematic review of dydrogesterone for the treatment of threatened miscarriage. Gynecol Endocrinol. 2012;28(12):983–90. — PubMed PMID: 22794306
10. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet. 2003;361(9361):901–8. — PubMed PMID: 12648968
11. Brigham SA, Conlon C, Farquharson RG. A longitudinal study of pregnancy outcome following idiopathic recurrent miscarriage. Hum Reprod. 1999;14(11):2868–71. — PubMed PMID: 10548638
12. Grande M, Borrell A, Garcia-Posada R, et al. The effect of maternal age on chromosomal anomaly rate and spectrum in recurrent miscarriage. Hum Reprod. 2012;27(10):3109–17. — PubMed PMID: 22888165
13. Rai R, Regan L. Recurrent miscarriage. Lancet. 2006;368(9535):601–11. — PubMed PMID: 16905025

↑ Back to Table of Contents

Connections

• Reproductive Medicine
• Fertilization: How Sperm Meets Egg — interactive animation
• Infertility
• Female Infertility
• Asherman's Syndrome
• Endometriosis
• Ovarian Torsion
• Ectopic Pregnancy
• Premature Ovarian Insufficiency
• Uterine Fibroids
• All Conditions

↑ Back to Table of Contents

Featured Videos